<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jaime-Ramirez AC</submitter><funding>NCI NIH HHS</funding><funding>NIH</funding><funding>NIGMS NIH HHS</funding><pagination>323-336</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4818694</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>4(4)</volume><pubmed_abstract>Optimally effective antitumor therapies would not only activate immune effector cells but also engage them at the tumor. Folate conjugated to immunoglobulin (F-IgG) could direct innate immune cells with Fc receptors to folate receptor-expressing cancer cells. F-IgG bound to human KB and HeLa cells, as well as murine L1210JF, a folate receptor (FR)-overexpressing cancer cell line, as determined by flow cytometry. Recognition of F-IgG by natural killer (NK) cell Fc receptors led to phosphorylation of the ERK transcription factor and increased NK cell expression of CD69. Lysis of KB tumor cells by NK cells increased by about 5-fold after treatment with F-IgG, an effect synergistically enhanced by treatment with IL2, IL12, IL15, or IL21 (P&lt; 0.001). F-IgG also enhanced the lysis of chronic lymp</pubmed_abstract><journal>Cancer immunology research</journal><pubmed_title>NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.</pubmed_title><pmcid>PMC4818694</pmcid><funding_grant_id>K24 CA093670</funding_grant_id><funding_grant_id>P30 CA16058</funding_grant_id><funding_grant_id>P30 CA016058</funding_grant_id><funding_grant_id>P01 CA095426</funding_grant_id><funding_grant_id>T32 CA90338-27</funding_grant_id><funding_grant_id>CA186542-01A1/Pelotonia</funding_grant_id><funding_grant_id>F32 CA186542</funding_grant_id><funding_grant_id>F32 CA186542-01A1</funding_grant_id><funding_grant_id>K24 CA93670</funding_grant_id><funding_grant_id>T32 GM068412</funding_grant_id><funding_grant_id>P01 CA95426</funding_grant_id><funding_grant_id>T32 GM068412/F32</funding_grant_id><pubmed_authors>Lee RJ</pubmed_authors><pubmed_authors>Butchar JP</pubmed_authors><pubmed_authors>Lu Y</pubmed_authors><pubmed_authors>Skinner CC</pubmed_authors><pubmed_authors>Mao H</pubmed_authors><pubmed_authors>Phelps M</pubmed_authors><pubmed_authors>Poi M</pubmed_authors><pubmed_authors>Davis M</pubmed_authors><pubmed_authors>La Perle KM</pubmed_authors><pubmed_authors>Karpa V</pubmed_authors><pubmed_authors>Luedke E</pubmed_authors><pubmed_authors>Byrd JC</pubmed_authors><pubmed_authors>Jarjoura D</pubmed_authors><pubmed_authors>Carson WE</pubmed_authors><pubmed_authors>McMichael E</pubmed_authors><pubmed_authors>Pan X</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Schmitt AC</pubmed_authors><pubmed_authors>Jaime-Ramirez AC</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Mundy-Bosse BL</pubmed_authors><pubmed_authors>Tridandapani S</pubmed_authors><pubmed_authors>Elavazhagan S</pubmed_authors><pubmed_authors>Kondadasula S</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Roda J</pubmed_authors><pubmed_authors>Caligiuri MA</pubmed_authors><pubmed_authors>Jones NB</pubmed_authors><pubmed_authors>Mani A</pubmed_authors></additional><is_claimable>false</is_claimable><name>NK Cell-Mediated Antitumor Effects of a Folate-Conjugated Immunoglobulin Are Enhanced by Cytokines.</name><description>Optimally effective antitumor therapies would not only activate immune effector cells but also engage them at the tumor. Folate conjugated to immunoglobulin (F-IgG) could direct innate immune cells with Fc receptors to folate receptor-expressing cancer cells. F-IgG bound to human KB and HeLa cells, as well as murine L1210JF, a folate receptor (FR)-overexpressing cancer cell line, as determined by flow cytometry. Recognition of F-IgG by natural killer (NK) cell Fc receptors led to phosphorylation of the ERK transcription factor and increased NK cell expression of CD69. Lysis of KB tumor cells by NK cells increased by about 5-fold after treatment with F-IgG, an effect synergistically enhanced by treatment with IL2, IL12, IL15, or IL21 (P&lt; 0.001). F-IgG also enhanced the lysis of chronic lymp</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 Apr</publication><modification>2025-04-04T11:59:39.786Z</modification><creation>2019-03-27T03:11:02Z</creation></dates><accession>S-EPMC4818694</accession><cross_references><pubmed>26865456</pubmed><doi>10.1158/2326-6066.cir-15-0168</doi><doi>10.1158/2326-6066.CIR-15-0168</doi></cross_references></HashMap>